Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, North America Commercial | March 06, 2023 | March 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 165,381 |
Last balance in matching sequence
After 2023-03-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-03-06 · Sale · Disposed 19,355 · Balance 223,447 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2023-03-07 · Sale · Disposed 58,066 · Balance 165,381 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2023 Filed Mar 8, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 58,066 | $9.43 | $547,440.44 |
DisclosureSEC source: 0001209191-23-017155 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,381 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 19,355 | $9.93 | $192,212.57 |
DisclosureSEC source: 0001209191-23-017155 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,447 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 24,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 7 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,905 Underlying: Ordinary Shares · 24,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 24,952 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 24,952 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 24,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016688 · doc4.xml · nonDerivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 38,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 6 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,617 Underlying: Ordinary Shares · 38,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,538 vested on March 4, 2023, 33,538 vesting on each of March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,538 vested on March 4, 2023, 33,538 vesting on each of March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 5 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 vested on each of March 4, 2021 and March 4, 2022, and 13,931 vested on March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 vested on each of March 4, 2021 and March 4, 2022, and 13,931 vested on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 38,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016688 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016688 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 99,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016688 · doc4.xml · derivative · entry 4 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,601 Underlying: Ordinary Shares · 99,601 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 42,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014436 · doc4.xml · derivative · entry 6 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 42,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F6 · derivative.expiration_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014436 · doc4.xml · derivative · entry 5 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,346 Underlying: Ordinary Shares · 17,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 17,346 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 17,346 vesting on February 28, 2024. F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 17,346 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 17,346 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 42,309 | $9.89 | $418,292.16 |
DisclosureSEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 4 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,381 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 42,309 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 17,346 | $9.89 | $171,492.96 |
DisclosureSEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,381 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014436 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 12:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 42,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007950 · doc4.xml · derivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,309 Underlying: Ordinary Shares · 42,309 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,993 | $7.37 | $51,515.33 |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 5 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,381 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 24,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 9 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,857 Underlying: Ordinary Shares · 24,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 24,952 having vested on March 5, 2022, 24,952 vesting on each of March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025. F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 24,952 having vested on March 5, 2022, 24,952 vesting on each of March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 24,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 4 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 154,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 8 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,155 Underlying: Ordinary Shares · 154,155 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 38,538 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026. F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 38,538 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 38,541 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 7 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,931 Underlying: Ordinary Shares · 13,930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023. F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 37,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · derivative · entry 6 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,939 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F7 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,904 | $7.48 | $29,211.68 |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,422 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,930 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 37,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017035 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014467 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,692 Underlying: Ordinary Shares · 17,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 17,346 having vested on each of February 28, 2021 and February 28, 2022, and 17,346 vesting on each of February 28, 2023 and February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 17,346 having vested on each of February 28, 2021 and February 28, 2022, and 17,346 vesting on each of February 28, 2023 and February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,862 | $8.14 | $39,587.38 |
DisclosureSEC source: 0001209191-22-014467 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,457 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014467 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008412 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,138 | $9.06 | $37,491.11 |
DisclosureSEC source: 0001209191-22-008412 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,973 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-008412 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 37,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008412 · doc4.xml · derivative · entry 4 Dethlefs Sven · CIK 0001726010 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,939 Underlying: Ordinary Shares · 37,939 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F7 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 99,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018510 · doc4.xml · derivative · entry 4 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,809 Underlying: Ordinary Shares · 99,809 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 24,952 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 24,953 vesting on March 5, 2025. F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 24,952 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 24,953 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018510 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,861 Underlying: Ordinary Shares · 13,930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,012 | $10.57 | $63,523.39 |
DisclosureSEC source: 0001209191-21-018510 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,975.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.690, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,930 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018510 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,987.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017756 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 606 | $10.86 | $6,582.74 |
DisclosureSEC source: 0001209191-21-017756 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,057.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.835 to $10.910, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017756 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,663.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 7,486 | $10.83 | $81,079.37 |
DisclosureSEC source: 0001209191-21-015826 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,263.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015826 · doc4.xml · derivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,038 Underlying: Ordinary Shares · 17,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 17,346 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 17,346 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015826 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,749.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009628 · doc4.xml · derivative · entry 5 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,135 Underlying: Ordinary Shares · 13,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 23,962 | $12.69 | $304,185.61 |
DisclosureSEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 4 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,403.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 5,695 | $12.69 | $72,295.18 |
DisclosureSEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 3 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,365.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 55,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,060.7 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009628 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,773.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:32 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020162 · doc4.xml · derivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F3 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:32 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020162 · doc4.xml · nonDerivative · entry 1 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,638.7 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016459 · doc4.xml · derivative · entry 2 Dethlefs Sven · CIK 0001726010 · EVP Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Ordinary Shares · 1,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.